Posting of Q&A

 26 November 2025

ANANDA PHARMA PLC

("Ananda" or the "Company")

Questions in relation to the Company's recent announcement about its proposed withdrawal from the AQSE Growth Market

Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF),  a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, announced on 24 November that it will be seeking approval from its shareholders via a General Meeting to withdraw admission of the Company's ordinary shares of £0.002 each ("Ordinary Shares") from trading on the AQSE Growth Market pursuant to Rule 5.3 of the AQSE Growth Market Rulebook, together with proposals to re-register the Company as a private limited company, adopt new articles of association and change its name to Ananda Pharma Limited. Details of this announcement can be found here and details of the General Meeting can be found here.

The Company has received a number of questions from shareholders about the proposals to be considered at the General Meeting. Those questions and the answers from management can be found on the company's website here: https://investors.anandapharma.co.uk/activity-updates/PGNgYr-questions-in-relation-to-the-companys-recent-announcement-about-its-proposed-withdrawal-from-the-aqse-growth-market

Shareholders are encouraged to read the Company's circular in respect of the Delisting. The contents of this Q&A are intended to provide a high-level overview of questions asked by Shareholders since publication of the circular and not to be construed as legal, business or tax advice. Prospective investors should consult their own professional advisers for legal, financial or tax advice in relation to an investment or proposed investment in the Company. The contents of this Q&A must not be relied upon when making any investment or voting decision in respect of the Company's shares.

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR). The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh.

For more information, please visit our website:

To stay up to date with Ananda's news please follow our social media channels:

· Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

· Instagram: https://www.instagram.com/anandapharmaplc/

· LinkedIn:  https://www.linkedin.com/company/anandapharma

· X: https://twitter.com/AnandaPlc

-Ends-

https://investors.anandapharma.co.uk/link/e9508e